| Zacks Company Profile for Novavax, Inc. (NVAX : NSDQ) |
|
|
| |
| • Company Description |
| Novavax, Inc. is a biotechnology company engaged in developing innovative vaccines to prevent serious infectious diseases. The company is also developing proprietary immune stimulating saponin-based adjuvants, namely Matrix-M, which already enhanced immune responses and were well-tolerated in multiple studies.?Novavax developed its own coronavirus vaccine NVX-CoV2373. The company is currently marketing two versions of NVX-CoV2373, one marketed in partnership with the Serum Institute of India under the trade name Covovax and another version produced by Novavax and marketed under the trade name Nuvaxovid.?Novavax developed NanoFlu, its recombinant quadrivalent seasonal influenza vaccine candidate with Matrix M adjuvant for senior patients aged 65 years and above.?ResVax a respiratory syncytial virus vaccine is being developed to protect infants by immunizing mothers against the disease. Novavax is discussing the opportunity to bring ResVax to the market globally with the help of commercial partners.
Number of Employees: 1,541 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $58.43 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 5,818,699 shares |
| Shares Outstanding: 78.14 (millions) |
| Market Capitalization: $4,565.40 (millions) |
| Beta: 1.59 |
| 52 Week High: $277.80 |
| 52 Week Low: $41.33 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
19.73% |
34.86% |
| 12 Week |
-26.92% |
-19.65% |
| Year To Date |
-59.16% |
-50.10% |
|
|
|
|
| |
| • Address & Contact Information |
| Street Address |
Phone / Fax |
Email Address |
Web URL |
21 FIRSTFIELD ROAD
-
GAITHERSBURG,MD 20878
USA |
ph: 240-268-2000
fax: 240-268-2100 |
ir@novavax.com |
http://www.novavax.com |
|
|
| |
| • General Corporate Information |
Officers
Stanley C. Erck - President and Chief Executive Officer
James F. Young - Chairman of the Board of Directors
James P. Kelly - Executive Vice President; Chief Financial Officer
Gregg H. Alton - Director
Richard H. Douglas - Director
|
|
Peer Information
Novavax, Inc. (CORR.)
Novavax, Inc. (RSPI)
Novavax, Inc. (CGXP)
Novavax, Inc. (BGEN)
Novavax, Inc. (GTBP)
Novavax, Inc. (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 670002401
SIC: 2836
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
|
|
Share - Related Items
Shares Outstanding: 78.14
Most Recent Split Date: 5.00 (0.05:1)
Beta: 1.59
Market Capitalization: $4,565.40 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $5.71 |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $25.77 |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: 4.00 |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 08/04/22 |
|
|
|
| |
